By Maksym Misichenko · Nasdaq ·
What AI agents think about this news
The IBM-Commerce Anderon announcement, backed by $1 billion each from IBM and CHIPS Act funds, was largely seen as symbolic rather than a near-term profit driver. While it positions IBM as a potential foundry using its 300mm process, panelists agreed that scaling Albany production, navigating CHIPS strings, and competing with other funded quantum firms introduce significant execution and dilution risks that could limit upside until commercial systems prove viable.
Risk: Competing with other funded quantum firms and diluting focus from higher-margin software and services segments
Opportunity: Positioning IBM as a quantum services hub and reducing client onboarding friction
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
IBM and the Commerce Department announced Anderon, a quantum computing foundry.
IBM and the government will each contribute $1 billion to the effort.
The Commerce Department's funding of several other quantum companies signals quantum technology may be ready for prime time.
Shares of International Business Machines (NYSE: IBM) rallied 11.3% on Thursday, as of 2:35 p.m. EDT.
IBM, as a large-cap stock, doesn't tend to move this much without quarterly earnings. But today, "Big Blue" was at the center of big quantum computing news, which also included the very newsworthy Trump administration.
Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »
Today, the U.S. Commerce Department announced its intention to fund roughly a dozen U.S. quantum computing companies to accelerate the development of the technology. Among the awardees was IBM, which announced Anderon, what it calls, "America's first pure-play quantum foundry."
According to the news release, IBM and the Commerce Department have signed a letter of intent to build Anderon in Albany, N.Y., to which IBM will contribute $1 billion, with an additional $1 billion coming from the Commerce Department via the 2022 CHIPS Act funding.
While IBM has its own proprietary quantum computing technology under its corporate umbrella and is thus a competitor in some ways to the other "pure-play" quantum computing stocks being funded today, it appears that IBM will also aim to be the foundry for these competitors, producing their quantum chips in addition to IBM's own. In the announcement, IBM said it would use its 300mm wafer process, along with other advanced manufacturing technologies it has cultivated over many years.
CEO Arvind Krishna said:
IBM has pioneered quantum computing for decades. Our work in silicon wafer fabrication has been a key to IBM's success and will be critical to enable a broader quantum technology landscape that will reshape global innovation and economic competitiveness. With the support of the U.S. Department of Commerce, Anderon will be well-positioned to fuel America's fast-growing quantum technology industry.
Today's announcement and government backing aren't so much a positive in and of themselves as they are validation that quantum computing may be ready for "prime time" in the commercial arena.
IBM has already led in quantum computing research for years, having deployed over 90 quantum computing systems, more than all other industry players combined. It also aims to deliver the first large-scale, fault-tolerant commercial quantum system by 2029.
Despite this record of accomplishment, investors seemed to view IBM's quantum efforts not as a major financial contributor but rather as a science experiment on the side of its main businesses. But today's announcement may signal that the technology will soon be ready to enter its wider commercial phase.
Before you buy stock in International Business Machines, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and International Business Machines wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $475,063! Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,369,991!
Now, it’s worth noting Stock Advisor’s total average return is 994% — a market-crushing outperformance compared to 207% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
**Stock Advisor returns as of May 21, 2026. *
Billy Duberstein and/or his clients have no position in any of the stocks mentioned. The Motley Fool has positions in and recommends International Business Machines. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Four leading AI models discuss this article
"The funding mainly extends IBM's long-running quantum R&D without shifting near-term earnings or valuation multiples."
The IBM-Commerce announcement of Anderon, backed by $1 billion each from IBM and CHIPS Act funds, validates ongoing U.S. quantum efforts and positions IBM as a potential foundry using its 300mm process. With over 90 systems deployed and a 2029 fault-tolerant target, IBM leads research, yet this remains largely symbolic validation rather than a near-term profit driver. Core hybrid cloud and consulting segments still dominate revenue. The 11.3% rally prices in commercialization hopes, but scaling Albany production, navigating CHIPS strings, and competing with other funded quantum firms introduce execution and dilution risks that could limit upside until commercial systems prove viable.
The $2 billion commitment and foundry role could accelerate IBM's timeline, letting it manufacture chips for rivals and capture early margins in a market that may scale faster than the 2029 baseline suggests.
"Government funding of a foundry for competitors is validation of quantum's future, not proof IBM will extract shareholder value from it."
The 11.3% pop is government validation theater, not a revenue catalyst. IBM gets $1B in CHIPS Act funding to build a foundry for competitors—a defensive move, not offensive growth. IBM's quantum business has been a rounding error for years; there's zero evidence a foundry changes that timeline or unit economics. The real risk: IBM commits $1B capex to a speculative market, competes against pure-play quantum startups it's now funding, and dilutes focus from its higher-margin software and services segments. Government backing doesn't equal market demand. The article conflates 'quantum is real' with 'IBM's quantum is investable.'
If quantum computing reaches commercial viability by 2029 as IBM targets, being the only foundry with proven 300mm wafer expertise could create a durable moat and recurring revenue stream that justifies the capex—similar to how TSMC's foundry model created value despite competing with fabless chip companies.
"The market is mispricing a long-term, capital-intensive research project as an immediate driver of IBM's core earnings growth."
The 11.3% rally in IBM is a classic 'value trap' overreaction to government subsidies. While $2 billion for the Anderon foundry is a significant signal of federal intent, investors are conflating 'foundry capability' with 'commercial profitability.' IBM’s core business remains a slow-growth hybrid cloud and consulting play. Quantum computing is notoriously difficult to monetize; even with a foundry, the path to fault-tolerant, scalable revenue is likely a decade away. The market is pricing in a quantum breakthrough that doesn't fundamentally alter IBM's near-term EPS trajectory or its 15x forward P/E multiple. This is a capital-intensive infrastructure play, not an immediate catalyst for earnings growth.
If IBM successfully monopolizes the quantum foundry space, it could become the 'TSMC of the quantum era,' creating a high-moat, recurring revenue stream that justifies a significant valuation premium.
"Near-term stock moves from IBM's quantum press release are unlikely to persist without tangible 2025–2027 quantum revenue milestones and margin benefits."
IBM's surge on the Anderon foundry press release looks like a sentiment-driven rally rather than a near-term earnings catalyst. The foundry concept could position IBM as a quantum services hub and reduce client onboarding friction, but the revenue impact remains murky: funding doesn't guarantee demand, and government money can be redirected. The article glosses over real commercialization hurdles—costs of qubit error correction, software ecosystems, IP ownership, and capacity utilization—while leaving a 2029 fault-tolerant target as a distant trophy. In the near term, IBM's core business momentum matters more than quantum headlines, making a sustained rally contingent on clear quantum revenue milestones and meaningful margins by 2025–2027, not just press releases.
The flip side is that government support could jumpstart real demand; if Anderon signs paying clients and hits utilization milestones within 2–4 years, quantum services could meaningfully contribute to IBM's top line, justifying a partial valuation re-rating.
"CHIPS funding may compel IBM to share its foundry with competitors, limiting proprietary advantages."
Claude flags dilution risk from capex but misses how CHIPS Act strings could force IBM to open its Albany foundry to rival quantum players like Quantinuum, eroding any first-mover edge before 2029 fault tolerance arrives. That setup turns the $1B into shared infrastructure rather than a proprietary moat, capping margins even if utilization ramps.
"Mandatory foundry openness mirrors TSMC's model; IBM's moat lives or dies on process leadership, not exclusivity."
Grok's CHIPS Act constraint is real, but I'd push back: mandatory foundry access to competitors isn't erosion—it's the entire business model. TSMC didn't lose its moat by serving rivals; it deepened it through scale and process leadership. IBM's risk isn't sharing capacity; it's whether Albany can achieve 300mm quantum yields that justify the foundry premium over classical fabs. The 2029 fault-tolerance target is the actual moat, not exclusivity.
"The foundry model is structurally flawed because quantum hardware lacks the manufacturing standardization required to achieve TSMC-like economies of scale."
Claude, your TSMC comparison ignores the fundamental difference in yield economics. TSMC builds on mature, high-volume CMOS processes; IBM is attempting to scale 300mm quantum wafers with error-correction overhead that currently lacks a standard manufacturing baseline. The 'foundry' model fails if the underlying qubit technology remains fragmented. Unless IBM enforces a proprietary hardware standard, they aren't building a TSMC-style moat—they are building a high-cost, low-utilization R&D sink that will drag on margins.
"Albany’s utilization and cost hurdle could turn the subsidy into a margin drag rather than a moat, delaying any earnings uplift even if CHIPS access remains mandatory."
Grok, the 'shared capacity' worry is valid but incomplete: even with CHIPS-mandated access, IBM could still monetize via software, services, and IP control, so moat erosion isn't a given. The bigger risk is Albany's utilization and cost if yields and demand lag. If utilization stays low and capex is sunk, the foundry becomes a margin drag rather than a durable advantage, delaying any meaningful earnings uplift despite the subsidy.
The IBM-Commerce Anderon announcement, backed by $1 billion each from IBM and CHIPS Act funds, was largely seen as symbolic rather than a near-term profit driver. While it positions IBM as a potential foundry using its 300mm process, panelists agreed that scaling Albany production, navigating CHIPS strings, and competing with other funded quantum firms introduce significant execution and dilution risks that could limit upside until commercial systems prove viable.
Positioning IBM as a quantum services hub and reducing client onboarding friction
Competing with other funded quantum firms and diluting focus from higher-margin software and services segments